Dr Richard Barker, the director general of the Association of the British Pharmaceutical Industry , says the National Institute for Health and Clinical Excellence should not set drug prices as part of the coalition government's planned value-based ...

As part of a new healthcare reform proposal, pharma companies in the US would be asked to pay a total of $2.3 billion in annual fees, depending on their market share, starting in 2010 1 . The proposal represents a bipartisan framework for ...

Japan?s Pharmaceuticals and Medical Devices Agency is set to undergo a significant change, with its focus shifting towards increased co-operation on the international stage. In its second mid-term plan, published on the PMDA?s website in April, the ...

Dr Richard Barker, the director general of the Association of the British Pharmaceutical Industry , says the National Institute for Health and Clinical Excellence should not set drug prices as part of the coalition government's planned value-based ...

The UK?s National Institute for Health and Clinical Excellence has boosted its capacity to assess the cost-effectiveness of new drugs and other treatments for use in the National Health Service by setting up a fourth technology appraisal committee 1 ...

The UK government and the life science industries have marked a year of action and progress for the Office for Life Sciences (OLS) with the release of a final report on its work to date and future plans. A lot has been written about the unique ...

The British government has announced plans for a new ?life sciences super cluster? to boost translational research and to help deliver the next generation of medicines and technologies needed to support people suffering from chronic diseases 1 . The ...

The US government has issued new regulations aimed at improving the protection of the genetic information of individuals undergoing genetic testing 1 , 2 . The regulations, issued on 1 October via an interim final rule, aim to help ensure that ...